Sirtex Medical Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sirtex Medical Limited - overview
Established
1997
Location
Sydney, NSW, Australia
Primary Industry
Biotechnology
About
Sirtex Medical Limited is a company focused on innovative cancer treatment solutions, notably through its SIR-Spheres® Y-90 resin microspheres for targeted liver cancer therapy. Sirtex Medical Limited specializes in the development of targeted therapies for liver tumors. Founded in 1997 in Sydney, Australia, the company has undergone significant changes, including a shift to a public-to-private model with a buyout for AUD 1. 87 billion in June 2018 by CDH Investments and China Grand Pharmaceutical and Healthcare Holdings Limited.
The company has secured AUD 1. 87 billion in total funding, with its latest deal occurring in May 2018. Sirtex Medical develops and commercializes innovative cancer treatments, primarily the SIR-Spheres® Y-90 resin microspheres for unresectable liver cancer. The company also offers the LAVA® Liquid Embolic System and SIROS™ INSYTE with SurePlan™ technology, catering to healthcare providers globally, particularly in the Asia-Pacific, Europe, and Latin America regions.
In the most recent fiscal year 2023, Sirtex Medical reported revenue of AUD 161,290,171. 60, with an EBITDA of AUD 19,996,137. 70, primarily generated from sales of SIR-Spheres® and other oncology solutions, reflecting a B2B sales model. Looking ahead, Sirtex Medical aims to enhance its product offerings with upcoming innovations in targeted therapies while expanding its market reach into new regions, particularly within Asia-Pacific and Latin America by 2025.
The recent funding round will support these initiatives, as the company continues to leverage its position in the oncology market following its privatization in June 2018.
Current Investors
CDH Investments, China Grand Pharmaceutical and Healthcare Holdings Limited
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.sirtex.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Sirtex Medical Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Public to Private | Completed | Sirtex Medical Limited | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.